Therapy of experimental NASH and fibrosis with galectin inhibitors.

by Peter G Traber, Eliezer Zomer
Published 2013-01-01

Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease.

by Peter G Traber, Hsin Chou, Eliezer Zomer, Feng Hong, Anatole Klyosov, Maria-Isabel Fiel, Scott L Friedman
Published 2013-01-01

Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity

by Elizabeth R. Sturgill, Annah S. Rolig, Stefanie N. Linch, Courtney Mick, Melissa J. Kasiewicz, Zhaoyu Sun, Peter G. Traber, Harold Shlevin, William L. Redmond
Published 2021-01-01

Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 random...

by Stephen A Harrison, Andrea Dennis, Martine M Fiore, Matt D Kelly, Catherine J Kelly, Angelo H Paredes, Jennifer M Whitehead, Stefan Neubauer, Peter G Traber, Rajarshi Banerjee
Published 2018-01-01

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

by William L Redmond, Yoshinobu Koguchi, Annah S Rolig, Noriko Iwamoto, Takashi Shimada, Elizabeth R Sturgill, Zhaoyu Sun, Venkatesh Rajamanickam, Brady Bernard, Peter G Traber, Eliezer Zomer, J Rex Horton, Harold Shlevin
Published 2021-04-01